4.7 Article

PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice

Journal

EXPERIMENTAL NEUROLOGY
Volume 232, Issue 2, Pages 333-338

Publisher

ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.expneurol.2011.09.005

Keywords

Dopamine; Behavior; Neurofibromin; Cyclic AMP; RAS

Categories

Funding

  1. National Cancer Institute [U01-CA141549]
  2. Department of Defense [NF093033]
  3. National Institute of Child Health and Human Development Center [P30 HD062171]
  4. Mallinckrodt Institute of Radiology

Ask authors/readers for more resources

Attention system abnormalities represent a significant barrier to scholastic achievement in children with neurofibromatosis-1 (NF1). Using a novel mouse model of NF1-associated attention deficit (ADD), we demonstrate a presynaptic defect in striatal dopaminergic homeostasis and leverage this finding to apply [(11)C]-raclopride positron-emission tomography (PET) in the intact animal. While methylphenidate and L-Deprenyl correct both striatal dopamine levels on PET imaging and defective attention system function in Nf1 mutant mice, pharmacologic agents that target de-regulated cyclic AMP and RAS signaling in these mice do not. These studies establish a robust preclinical model to evaluate promising agents for NF1-associated ADD. (C) 2011 Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available